Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Tianeptine as an opiate replacement in a patient on methadone treatment: A case report
J Opioid Manag. 2024 Jan-Feb;20(1):87-91. doi: 10.5055/jom.0851.ABSTRACTTianeptine, an antidepressant and full µ-opioid receptor agonist, has increased in popularity and has been used as an over-the-counter supplement over the past decade. Due to its well-documented euphoric effects, there exists elevated risk for potential abuse. Buprenorphine-naloxone has been successfully utilized to treat opioid use disorder (OUD) in patients concurrently using tianeptine, limiting withdrawal symptoms and abstinence. However, there is limited evidence on the management of tianeptine use disorder, specifically methadone or naltrexone. ...
Source: Journal of Opioid Management - March 27, 2024 Category: Addiction Authors: Vivek Velagapudi Jordan Calabrese Roopa Sethi Source Type: research
